Fig. 7: SERCA activator CDN1163 partially rescued the PKD2 deficiency-associated contractile deficiency. | Cell Death & Disease

Fig. 7: SERCA activator CDN1163 partially rescued the PKD2 deficiency-associated contractile deficiency.

From: Investigating PKD2 deficiency-associated cardiomyopathies using hESC-cardiomyocytes and bioengineered 3D ventricular cardiac tissue strips

Fig. 7: SERCA activator CDN1163 partially rescued the PKD2 deficiency-associated contractile deficiency.The alternative text for this image may have been generated using AI.

A Representative contractile traces of H7-CMs-hvCTS under 1 Hz electrical pacing before (black trace) and after (red or blue trace) 1 hr treatment with 1 μM CDN1163. The hvCTS samples with PKD2 knockdown are on the right, whereas those without PKD2 knockdown are on the left. Data summary showing that CDN1163 treatment improved the contractile function in hvCTS samples with or without PKD2 knockdown, regarding developed force (B), passive tension (C), rise time 90 (D), and decay time 90 (E). Mean ± SEM. n = 7. *P < 0.05; **P < 0.01; ***P < 0.001.

Back to article page